Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy Compared with Chemotherapy as First-Line Treatment for Advanced PD-L1-Positive Triple-Negative Breast Cancer from a Japanese Healthcare Perspective
Clinical Drug Investigation · 2025
DOI: 10.1007/s40261-025-01445-8 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Drug Investigation, 2025. Verfasst von Yugo Chisaki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Education and Research Center for Clinical Pharmacy, Kyoto Pharmaceutical University, 5-Nakauchi-cho, Misasagi, Yamashina-ku, Kyoto, 607-8414, Japan.…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVES: Pembrolizumab has been approved for the immunotherapy of programmed death ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC) based on the KEYNOTE-355 trial. However, cost-effectiveness evidence is limited. The purpose of this study was to evaluate the cost-effectiveness of pembrolizumab plus chemotherapy compared with chemotherapy alone for patients with PD-L1-positive inoperable or metastatic TNBC from a Japanese healthcare perspective. METHODS: The cost-effectiveness analysis was performed for pembrolizumab, of which the drug price was determined at 214,498 Japanese yen (JPY), or 1631 US dollars (USD) (1 USD = 131.5 JPY) for KEYTRUDA® (100 mg), using a partition survival model based on the KEYNOTE-355 trial subgroup analysis in Japan. The comparison was made using quality-adjusted life years (QALYs) and the incremental cost-effectiveness ratio (ICER). One-way deterministic and probabilistic sensitivity analyses (PSA), which evaluate the impact of parameter uncertainty, were performed to assess the robustness and calculate the acceptable probability, defined as the probability of the ICER being below the willingness-to-pay (WTP). RESULTS: Pembrolizumab plus chemotherapy provided an additional 0.676 QALYs at an incremental cost of 8,503,072 JPY. The ICER for pembrolizumab plus chemotherapy compared with conventional chemotherapy was 12,577,178 JPY (95,644 USD) per QALY. The ICER per QALY was below the willingness-to-pay threshold of 15,000,000 JPY. PSAs revealed that the acceptable probability was 83.9% at 15,000,000 JPY. CONCLUSIONS: The pembrolizumab plus chemotherapy is likely to be a cost-effective option compared with conventional chemotherapy for patients with PD-L1-positive inoperable or metastatic TNBC in a Japanese medical environment from a healthcare system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Education and Research Center for Clinical Pharmacy, Kyoto Pharmaceutical University, 5-Nakauchi-cho, Misasagi, Yamashina-ku, Kyoto, 607-8414, Japan. chisaki@mb.kyoto-phu.ac.jp.
- Education and Research Center for Clinical Pharmacy, Kyoto Pharmaceutical University, 5-Nakauchi-cho, Misasagi, Yamashina-ku, Kyoto, 607-8414, Japan.
Zitieren
APA
Chisaki, Y., Nakamura, N., Komuro, T., Nyuji, H., Harano, M., & Kitada, N. (2025). Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy Compared with Chemotherapy as First-Line Treatment for Advanced PD-L1-Positive Triple-Negative Breast Cancer from a Japanese Healthcare Perspective. Clinical Drug Investigation. https://doi.org/10.1007/s40261-025-01445-8
Vancouver
Chisaki Y, Nakamura N, Komuro T, Nyuji H, Harano M, Kitada N. Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy Compared with Chemotherapy as First-Line Treatment for Advanced PD-L1-Positive Triple-Negative Breast Cancer from a Japanese Healthcare Perspective. Clinical Drug Investigation. 2025. doi:10.1007/s40261-025-01445-8
BibTeX
@article{Chisaki2025,
author = {Chisaki, Yugo and Nakamura, Nobuhiko and Komuro, Takako and Nyuji, Hirokatsu and Harano, Mai and Kitada, Noriaki},
title = {Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy Compared with Chemotherapy as First-Line Treatment for Advanced PD-L1-Positive Triple-Negative Breast Cancer from a Japanese Healthcare Perspective},
journal = {Clinical Drug Investigation},
year = {2025},
doi = {10.1007/s40261-025-01445-8}
}
EUVIMED